160 related articles for article (PubMed ID: 28592183)
21. Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.
Weinrib R; Browne EN; Shapley-Quinn MK; van der Straten A; Beksinska M; Mgodi N; Musara P; Mphili N; Schwartz JL; Ju S; Hanif H; Montgomery ET;
AIDS Behav; 2020 Feb; 24(2):637-647. PubMed ID: 31254190
[TBL] [Abstract][Full Text] [Related]
22. Specific microbicides in the prevention of HIV infection.
Kelly CG; Shattock RJ
J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
[TBL] [Abstract][Full Text] [Related]
23. Challenges of introducing vaginal microbicides in India.
Joshi S; Kulkarni V; Paranjape R; Chandhiok N
Indian J Med Res; 2009 May; 129(5):618-9. PubMed ID: 19675395
[No Abstract] [Full Text] [Related]
24. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.
Braunstein S; van de Wijgert J
J Womens Health (Larchmt); 2005 Jun; 14(5):424-33. PubMed ID: 15989415
[TBL] [Abstract][Full Text] [Related]
25. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
Joanis CL; Hart CW
AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522
[TBL] [Abstract][Full Text] [Related]
26. Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties.
Morrow KM; Fava JL; Rosen RK; Vargas S; Barroso C; Christensen AL; Woodsong C; Severy L
J Acquir Immune Defic Syndr; 2007 May; 45(1):93-101. PubMed ID: 17325607
[TBL] [Abstract][Full Text] [Related]
27. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices.
Moench TR; Chipato T; Padian NS
AIDS; 2001 Sep; 15(13):1595-602. PubMed ID: 11546933
[No Abstract] [Full Text] [Related]
28. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study.
Montgomery ET; Beksinska M; Mgodi N; Schwartz J; Weinrib R; Browne EN; Mphili N; Musara P; Jaggernath M; Ju S; Smit J; Chirenje ZM; Doncel GF; van der Straten A
J Int AIDS Soc; 2019 May; 22(5):e25283. PubMed ID: 31069957
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
[TBL] [Abstract][Full Text] [Related]
30. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
Giguere R; Carballo-Diéguez A; Ventuneac A; Mabragaña M; Dolezal C; Chen BA; Kahn JA; Zimet GD; McGowan I
Cult Health Sex; 2012; 14(2):151-66. PubMed ID: 22084840
[TBL] [Abstract][Full Text] [Related]
31. Improving topical microbicide applicators for use in resource-poor settings.
Vail JG; Cohen JA; Kelly KL
Am J Public Health; 2004 Jul; 94(7):1089-92. PubMed ID: 15226124
[TBL] [Abstract][Full Text] [Related]
32. Shape of vaginal suppositories affects willingness-to-try and preference.
Li B; Zaveri T; Ziegler GR; Hayes JE
Antiviral Res; 2013 Mar; 97(3):280-4. PubMed ID: 23276592
[TBL] [Abstract][Full Text] [Related]
33. Recent advances on anti-HIV vaginal delivery systems development.
Antimisiaris SG; Mourtas S
Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
[TBL] [Abstract][Full Text] [Related]
34. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women.
Nel AM; Mitchnick LB; Risha P; Muungo LT; Norick PM
J Womens Health (Larchmt); 2011 Aug; 20(8):1207-14. PubMed ID: 21774672
[TBL] [Abstract][Full Text] [Related]
35. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Carballo-Diéguez A; Balán IC; Morrow K; Rosen R; Mantell JE; Gai F; Hoffman S; Maslankowski L; El-Sadr W; Mayer K
AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
[TBL] [Abstract][Full Text] [Related]
36. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?
Elias C; Coggins C
J Womens Health Gend Based Med; 2001 Mar; 10(2):163-73. PubMed ID: 11268299
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
[TBL] [Abstract][Full Text] [Related]
38. The future of HIV microbicides: challenges and opportunities.
Garg AB; Nuttall J; Romano J
Antivir Chem Chemother; 2009; 19(4):143-50. PubMed ID: 19374141
[TBL] [Abstract][Full Text] [Related]
39. End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.
Weinrib R; Minnis A; Agot K; Ahmed K; Owino F; Manenzhe K; Cheng H; van der Straten A
AIDS Behav; 2018 Jan; 22(1):133-145. PubMed ID: 29052018
[TBL] [Abstract][Full Text] [Related]
40. Desired qualities and hypothetical contextual use of vaginal microbicides in a diverse sample of US women.
Olsen ML; Cwiak CA; Koudelka C; Jensen JT
Contraception; 2007 Oct; 76(4):314-8. PubMed ID: 17900444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
